Solventum Corporation (SOLV) EV/Sales Ratio: 2.23x
Is Solventum Corporation’s EV/Sales ratio high or low?
Solventum Corporation's EV/Sales ratio of 2.23x is in line with its 2-year average of 2.26x, around the middle of its 2-year range (1.80x–2.67x).
As of Friday, June 12, 2026. 1.81% above its 12-month average of 2.19x.
SOLV EV/Sales Ratio Chart
SOLV Average EV/Sales Ratio Chart
SOLV Current vs Average EV/Sales Ratio Chart
SOLV EV/Sales Ratio Metrics
EV/SALES RATIO
2.23x
EV/SALES RATIO AVG TTM
2.19x
EV/SALES RATIO AVG 3Y
2.26x
EV/SALES RATIO AVG 5Y
2.26x
EV/SALES RATIO AVG 10Y
2.26x
EV/SALES RATIO AVG 15Y
2.26x
EV/SALES RATIO AVG 20Y
2.26x
CURRENT VS TTM AVG
+1.81%
CURRENT VS 3Y AVG
-1.25%
CURRENT VS 5Y AVG
-1.25%
CURRENT VS 10Y AVG
-1.25%
CURRENT VS 15Y AVG
-1.25%
CURRENT VS 20Y AVG
-1.25%
SOLV Competitors' EV/Sales Ratio
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Solventum Corporation (SOLV) | $13.72B | 2.23x | 2.19x | 2.26x | 2.26x |
| Align Technology, Inc. (ALGN) | $12.27B | 2.75x | 2.73x | 4.07x | 5.91x |
| Baxter International Inc. (BAX) | $10.58B | 1.61x | 1.72x | 2.17x | 2.64x |
| Hologic, Inc. (HOLX) | $16.97B | 4.25x | 4.02x | 4.39x | 4.15x |
| Charles River Laboratories International, Inc. (CRL) | $8.94B | 2.97x | 2.79x | 3.02x | 3.79x |
| Moderna, Inc. (MRNA) | $18.71B | 8.10x | 5.96x | 5.02x | 6.82x |
| Tempus AI, Inc. (TEM) | $8.65B | 6.72x | 11.47x | 12.18x | 12.18x |
| Bio-Rad Laboratories, Inc. (BIO) | $7.92B | 3.41x | 3.41x | 3.67x | 4.57x |
| Hims & Hers Health, Inc. (HIMS) | $6.19B | 3.06x | 4.73x | 4.20x | 4.27x |
| BioNTech SE (BNTX) | $22.39B | 3.24x | 4.19x | 3.71x | 3.49x |
Understanding EV/Sales
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
- It works for unprofitable companies where P/E doesn't apply
- Revenue is harder to manipulate than earnings
- It supports comparisons across companies at different profitability stages
- It is frequently used for software and other revenue-growth-focused companies
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
Solventum Corporation EV/Sales Ratio Formula & Definition
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Solventum Corporation EV/Sales Ratio FAQ
- What is the EV/Sales ratio for Solventum Corporation (SOLV)?
- The EV/Sales ratio for SOLV stock is 2.23x.
- Is Solventum Corporation's EV/Sales ratio high or low?
- Solventum Corporation's EV/Sales ratio of 2.23x is in line with its 2-year average of 2.26x, around the middle of its 2-year range (1.80x–2.67x).
- What is the TTM average EV/Sales ratio for Solventum Corporation (SOLV)?
- The TTM average EV/Sales ratio for SOLV stock is 2.19x.
- What is the 3Y average EV/Sales ratio for Solventum Corporation (SOLV)?
- The 3Y average EV/Sales ratio for SOLV stock is 2.26x.
- What is the 5Y average EV/Sales ratio for Solventum Corporation (SOLV)?
- The 5Y average EV/Sales ratio for SOLV stock is 2.26x.
- What is the 10Y average EV/Sales ratio for Solventum Corporation (SOLV)?
- The 10Y average EV/Sales ratio for SOLV stock is 2.26x.
- What is the 15Y average EV/Sales ratio for Solventum Corporation (SOLV)?
- The 15Y average EV/Sales ratio for SOLV stock is 2.26x.
- What is the 20Y average EV/Sales ratio for Solventum Corporation (SOLV)?
- The 20Y average EV/Sales ratio for SOLV stock is 2.26x.
Solventum Corporation EV/Sales Ratio History
| DATE | EV/SALES RATIO |
|---|---|
| 2026-06-11 | 2.23x |
| 2026-06-10 | 2.27x |
| 2026-06-09 | 2.30x |
| 2026-06-08 | 2.22x |
| 2026-06-05 | 2.27x |
| 2026-06-04 | 2.30x |
| 2026-06-03 | 2.21x |
| 2026-06-02 | 2.17x |
| 2026-06-01 | 2.16x |
| 2026-05-29 | 2.14x |
| 2026-05-28 | 2.16x |
| 2026-05-27 | 2.16x |
| 2026-05-26 | 2.17x |
| 2026-05-22 | 2.18x |
| 2026-05-21 | 2.18x |
| 2026-05-20 | 2.16x |
| 2026-05-19 | 2.13x |
| 2026-05-18 | 2.16x |
| 2026-05-15 | 2.12x |
| 2026-05-14 | 2.13x |
| 2026-05-13 | 2.13x |
| 2026-05-12 | 2.14x |
| 2026-05-11 | 2.12x |
| 2026-05-08 | 2.11x |
| 2026-05-07 | 2.07x |
| 2026-05-06 | 2.06x |
| 2026-05-05 | 2.01x |
| 2026-05-04 | 1.92x |
| 2026-05-01 | 1.90x |
| 2026-04-30 | 1.92x |
| 2026-04-29 | 1.90x |
| 2026-04-28 | 1.92x |
| 2026-04-27 | 1.97x |
| 2026-04-24 | 1.94x |
| 2026-04-23 | 1.95x |
| 2026-04-22 | 1.95x |
| 2026-04-21 | 1.95x |
| 2026-04-20 | 1.97x |
| 2026-04-17 | 1.98x |
| 2026-04-16 | 1.95x |
| 2026-04-15 | 1.95x |
| 2026-04-14 | 1.95x |
| 2026-04-13 | 1.92x |
| 2026-04-10 | 1.88x |
| 2026-04-09 | 1.89x |
| 2026-04-08 | 1.87x |
| 2026-04-07 | 1.82x |
| 2026-04-06 | 1.83x |
| 2026-04-02 | 1.84x |
| 2026-04-01 | 1.85x |
| 2026-03-31 | 1.87x |
| 2026-03-30 | 1.84x |
| 2026-03-27 | 1.82x |
| 2026-03-26 | 1.86x |
| 2026-03-25 | 1.86x |
| 2026-03-24 | 1.85x |
| 2026-03-23 | 1.88x |
| 2026-03-20 | 1.88x |
| 2026-03-19 | 1.91x |
| 2026-03-18 | 1.91x |
| 2026-03-17 | 1.95x |
| 2026-03-16 | 1.91x |
| 2026-03-13 | 1.91x |
| 2026-03-12 | 1.89x |
| 2026-03-11 | 1.92x |
| 2026-03-10 | 1.92x |
| 2026-03-09 | 1.94x |
| 2026-03-06 | 1.96x |
| 2026-03-05 | 1.99x |
| 2026-03-04 | 1.98x |
| 2026-03-03 | 1.99x |
| 2026-03-02 | 2.04x |
| 2026-02-27 | 2.06x |
| 2026-02-26 | 2.02x |
| 2026-02-25 | 1.98x |
| 2026-02-24 | 1.95x |
| 2026-02-23 | 1.93x |
| 2026-02-20 | 1.94x |
| 2026-02-19 | 1.95x |
| 2026-02-18 | 1.98x |
| 2026-02-17 | 1.96x |
| 2026-02-13 | 1.99x |
| 2026-02-12 | 2.00x |
| 2026-02-11 | 2.12x |
| 2026-02-10 | 2.10x |
| 2026-02-09 | 2.05x |
| 2026-02-06 | 2.05x |
| 2026-02-05 | 2.02x |
| 2026-02-04 | 2.01x |
| 2026-02-03 | 2.00x |
| 2026-02-02 | 2.02x |
| 2026-01-30 | 2.02x |
| 2026-01-29 | 2.01x |
| 2026-01-28 | 2.02x |
| 2026-01-27 | 2.04x |
| 2026-01-26 | 2.07x |
| 2026-01-23 | 2.06x |
| 2026-01-22 | 2.09x |
| 2026-01-21 | 2.09x |
| 2026-01-20 | 2.06x |
| 2026-01-16 | 2.08x |
| 2026-01-15 | 2.10x |
| 2026-01-14 | 2.09x |
| 2026-01-13 | 2.09x |
| 2026-01-12 | 2.20x |
| 2026-01-09 | 2.21x |
| 2026-01-08 | 2.21x |
| 2026-01-07 | 2.17x |
| 2026-01-06 | 2.15x |
| 2026-01-05 | 2.10x |
| 2026-01-02 | 2.07x |
| 2025-12-31 | 2.07x |
| 2025-12-30 | 2.09x |
| 2025-12-29 | 2.09x |
| 2025-12-26 | 2.10x |
| 2025-12-24 | 2.09x |
| 2025-12-23 | 2.10x |
| 2025-12-22 | 2.10x |
| 2025-12-19 | 2.12x |
| 2025-12-18 | 2.10x |
| 2025-12-17 | 2.09x |
| 2025-12-16 | 2.10x |
| 2025-12-15 | 2.13x |
| 2025-12-12 | 2.15x |
| 2025-12-11 | 2.14x |
| 2025-12-10 | 2.13x |
| 2025-12-09 | 2.09x |
| 2025-12-08 | 2.14x |
| 2025-12-05 | 2.20x |
| 2025-12-04 | 2.20x |
| 2025-12-03 | 2.20x |
| 2025-12-02 | 2.20x |
| 2025-12-01 | 2.20x |
| 2025-11-28 | 2.20x |
| 2025-11-26 | 2.20x |
| 2025-11-25 | 2.21x |
| 2025-11-24 | 2.16x |
| 2025-11-21 | 2.15x |
| 2025-11-20 | 2.08x |
| 2025-11-19 | 2.03x |
| 2025-11-18 | 2.02x |
| 2025-11-17 | 2.01x |
| 2025-11-14 | 2.00x |
| 2025-11-13 | 1.99x |
| 2025-11-12 | 1.96x |
| 2025-11-11 | 1.96x |
| 2025-11-10 | 1.91x |
| 2025-11-07 | 1.91x |
| 2025-11-06 | 1.80x |
| 2025-11-05 | 2.29x |
| 2025-11-04 | 2.31x |
| 2025-11-03 | 2.30x |
| 2025-10-31 | 2.32x |
| 2025-10-30 | 2.32x |
| 2025-10-29 | 2.33x |
| 2025-10-28 | 2.35x |
| 2025-10-27 | 2.38x |
| 2025-10-24 | 2.37x |
| 2025-10-23 | 2.38x |
| 2025-10-22 | 2.39x |
| 2025-10-21 | 2.40x |
| 2025-10-20 | 2.40x |
| 2025-10-17 | 2.38x |
| 2025-10-16 | 2.37x |
| 2025-10-15 | 2.37x |
| 2025-10-14 | 2.37x |
| 2025-10-13 | 2.35x |
| 2025-10-10 | 2.35x |
| 2025-10-09 | 2.37x |
| 2025-10-08 | 2.39x |
| 2025-10-07 | 2.38x |
| 2025-10-06 | 2.41x |
| 2025-10-03 | 2.42x |
| 2025-10-02 | 2.43x |
| 2025-10-01 | 2.40x |
| 2025-09-30 | 2.40x |
| 2025-09-29 | 2.38x |
| 2025-09-26 | 2.36x |
| 2025-09-25 | 2.34x |
| 2025-09-24 | 2.37x |
| 2025-09-23 | 2.41x |
| 2025-09-22 | 2.41x |
| 2025-09-19 | 2.41x |
| 2025-09-18 | 2.43x |
| 2025-09-17 | 2.42x |
| 2025-09-16 | 2.42x |
| 2025-09-15 | 2.40x |
| 2025-09-12 | 2.41x |
| 2025-09-11 | 2.41x |
| 2025-09-10 | 2.36x |
| 2025-09-09 | 2.40x |
| 2025-09-08 | 2.43x |
| 2025-09-05 | 2.39x |
| 2025-09-04 | 2.38x |
| 2025-09-03 | 2.36x |
| 2025-09-02 | 2.37x |
| 2025-08-29 | 2.40x |
| 2025-08-28 | 2.39x |
| 2025-08-27 | 2.40x |
| 2025-08-26 | 2.40x |
| 2025-08-25 | 2.39x |
| 2025-08-22 | 2.41x |
| 2025-08-21 | 2.38x |
| 2025-08-20 | 2.39x |
| 2025-08-19 | 2.38x |
| 2025-08-18 | 2.35x |
| 2025-08-15 | 2.36x |
| 2025-08-14 | 2.40x |
| 2025-08-13 | 2.43x |
| 2025-08-12 | 2.38x |
| 2025-08-11 | 2.37x |
| 2025-08-08 | 2.41x |
| 2025-08-07 | 2.38x |
| 2025-08-06 | 2.42x |
| 2025-08-05 | 2.41x |
| 2025-08-04 | 2.43x |
| 2025-08-01 | 2.40x |
| 2025-07-31 | 2.39x |
| 2025-07-30 | 2.42x |
| 2025-07-29 | 2.44x |
| 2025-07-28 | 2.44x |
| 2025-07-25 | 2.46x |
| 2025-07-24 | 2.44x |
| 2025-07-23 | 2.45x |
| 2025-07-22 | 2.42x |
| 2025-07-21 | 2.41x |
| 2025-07-18 | 2.43x |
| 2025-07-17 | 2.44x |
| 2025-07-16 | 2.42x |
| 2025-07-15 | 2.44x |
| 2025-07-14 | 2.45x |
| 2025-07-11 | 2.44x |
| 2025-07-10 | 2.48x |
| 2025-07-09 | 2.45x |
| 2025-07-08 | 2.47x |
| 2025-07-07 | 2.49x |
| 2025-07-03 | 2.54x |
| 2025-07-02 | 2.53x |
| 2025-07-01 | 2.53x |
| 2025-06-30 | 2.48x |
| 2025-06-27 | 2.48x |
| 2025-06-26 | 2.46x |
| 2025-06-25 | 2.47x |
| 2025-06-24 | 2.47x |
| 2025-06-23 | 2.43x |
| 2025-06-20 | 2.44x |
| 2025-06-18 | 2.42x |
| 2025-06-17 | 2.42x |
| 2025-06-16 | 2.45x |
| 2025-06-13 | 2.44x |
| 2025-06-12 | 2.45x |
| 2025-06-11 | 2.45x |
| 2025-06-10 | 2.48x |
| 2025-06-09 | 2.46x |
| 2025-06-06 | 2.46x |
| 2025-06-05 | 2.47x |
| 2025-06-04 | 2.47x |
| 2025-06-03 | 2.45x |
| 2025-06-02 | 2.43x |
| 2025-05-30 | 2.43x |
Showing the most recent 260 of 555 data points. The chart above shows the full history.
Related Metrics
About Solventum Corporation
Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments. The Medsurg division furnishes various products and services, including sophisticated wound care items, intravenous (I.V.) site management tools, sterilization assurance systems, temperature regulation devices, surgical instruments, stethoscopes, and medical electrodes. Its Dental Solutions segment provides a comprehensive range of dental and orthodontic offerings, such as brackets, clear aligners, restorative filling materials, and bonding agents. The Health Information Systems division concentrates on advanced software platforms, covering functionalities like computer-assisted physician documentation, direct billing and coding automation, classification frameworks, voice recognition capabilities, and data visualization tools. Finally, the Purification and Filtration segment supplies an array of purification and filtration technologies, including various filters, purifiers, cartridges, and specialized membranes.
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- CEO
- Bryan C. Hanson